DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: TAK-981
Drug: Pembrolizumab

First Posted Date: 2020-05-11

Last Posted Date: 2025-04-02

Lead Sponsor: Takeda

Target Recruit Count: 109

Registration Number: NCT04381650

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of California Irvine Medical Center, Orange, California, United States

and more 49 locations

ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice

Withdrawn

Conditions: Crohn Disease

First Posted Date: 2020-04-16

Last Posted Date: 2020-10-06

Lead Sponsor: Takeda

Registration Number: NCT04349449

Locations: 🇨🇦
Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada
🇨🇦
REGIONAL HEALTH AUTHORITY B doing business as HORIZON HEALTH NETWORK, Fredericton, New Brunswick, Canada
🇨🇦
Nova ScotiaHealth Authority, Halifax, Nova Scotia, Canada

and more 11 locations

A Study of TAK-071 in People With Parkinson Disease

Phase 2

Completed

Conditions: Parkinson Disease
Healthy Participants

Interventions: Drug: TAK-071
Drug: Placebo

First Posted Date: 2020-04-06

Last Posted Date: 2024-05-14

Lead Sponsor: Takeda

Target Recruit Count: 64

Registration Number: NCT04334317

Locations: 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Augusta University, Augusta, Georgia, United States

and more 18 locations

A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting

Conditions: Multiple Myeloma
Neoplasms, Plasma Cell

First Posted Date: 2020-03-31

Last Posted Date: 2025-04-10

Lead Sponsor: Takeda

Target Recruit Count: 482

Registration Number: NCT04328662

Locations: 🇨🇳
Beijing Chao-yang Hospital,Capital Medical University(Shijingshan), Beijing, Beijing, China
🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳
Beijing Chao-yang Hospital,Capital Medical University, Beijing, Beijing, China

and more 25 locations

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: 9vHPV Vaccine
Biological: Dengue Tetravalent Vaccine (TDV)

First Posted Date: 2020-03-18

Last Posted Date: 2024-02-07

Lead Sponsor: Takeda

Target Recruit Count: 614

Registration Number: NCT04313244

Locations: 🇹🇭
Siriraj Hospital, Bangkoknoi, Khet Bangkok Noi, Thailand
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭
The Hospital for Tropical Diseases, Bangkok, Thailand

and more 1 locations

A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation

Withdrawn

Conditions: Gastroesophageal Reflux Disease

First Posted Date: 2020-03-17

Last Posted Date: 2020-04-14

Lead Sponsor: Takeda

Registration Number: NCT04311541

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin

First Posted Date: 2020-02-26

Last Posted Date: 2024-08-23

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT04285983

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Phase 2

Completed

Conditions: Primary Immune Thrombocytopenia

Interventions: Drug: TAK-079
Drug: Placebo

First Posted Date: 2020-02-20

Last Posted Date: 2024-10-14

Lead Sponsor: Takeda

Target Recruit Count: 41

Registration Number: NCT04278924

Locations: 🇧🇬
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia, Sofia-Grad, Bulgaria
🇸🇮
Univerzitetni klinicni Center Ljubljana, Ljubljana, Slovenia
🇧🇬
University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria

and more 52 locations

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase 1

Terminated

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2020-02-17

Last Posted Date: 2020-03-17

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT04272775

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Pevonedistat
Drug: Azacitidine

First Posted Date: 2020-02-12

Last Posted Date: 2024-12-17

Lead Sponsor: Takeda

Target Recruit Count: 164

Registration Number: NCT04266795

Locations: 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 54 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy